Topspin Partners II

Topspin Partners II, established in 2014, is a New York-based private equity firm focused on lower mid-market investments. It primarily targets consumer sectors across the United States, including manufacturing, information technology, consumer products and services, and healthcare. The firm, an affiliate of Renaissance Technologies, works with management teams to build and grow companies, aiming to generate superior returns through strategic partnerships and a long-term approach.

Stephen Parks

Partner

Ekta Sharma

Principal

Ojas Vahia

Partner

Steve Winick

Managing Director

72 past transactions

Mission Product Holdings

Private Equity Round in 2022
Mission Product Holdings, Inc. specializes in manufacturing and distributing athletic and performance apparel and accessories for both men and women. The company offers a diverse range of products, including t-shirts, tank tops, jackets, shorts, leggings, and accessories such as cooling towels and headbands. Notably, Mission is recognized for its innovative athlete-engineered products aimed at enhancing performance during training and competition. Its portfolio features advanced thermo-regulation technology that helps control body temperature, thereby improving athletic performance. The company markets its temperature control products under various brand names, including HydroActive MAX, RadiantActive, and Vaporactive. Mission Product Holdings was incorporated in 2007 and is headquartered in New York, New York, with products available through online retail channels.

Coop Home Goods

Private Equity Round in 2021
Coop Home Goods is a manufacturer of bedding products focused on enhancing the sleeping experience. The company specializes in adjustable pillows designed to accommodate various body types and sleep positions, allowing users to customize the fill for optimal alignment and comfort. In addition to pillows, Coop offers a range of products including comforters, mattress pads, bedding sets, pet beds, and various types of support and throw pillows. The materials used in their products are breathable, promoting proper airflow and contributing to a comfortable sleep environment. Customer inquiries are addressed through multiple channels, including phone, email, and online applications.

SportPet Designs

Private Equity Round in 2021
SportPet Designs is a well-established manufacturer and marketer of a wide range of pet products, including branded and private label items. The company specializes in creating furniture, scratchers, beds, and toys for pets, offering a diverse selection that caters to the needs of both dogs and cats. Its product line includes elevated dog beds, deluxe mattress beds, cat carriers, and luxury sofa beds, all designed to ensure comfort and safety for pets. SportPet Designs is committed to providing high-quality, environmentally responsible products, making it a trusted choice for pet owners seeking durable and stylish solutions for their animals.

reCommerce

Venture Round in 2020
reCommerce is a full-service brand agency that assists international brands in optimizing their Amazon presence and increasing sales.

Codagenix

Series B in 2020
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.

PMV Pharmaceuticals

Series C in 2019
PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

JD Beauty

Acquisition in 2019
JD Beauty Group is the perfect company to ensure that you are on the top of your beauty products game. Their product quality, selection, diversity, and prices are the best in the industry. They are commited to using only the best materials in concert with the finest craftsmanship.

Japonesque

Acquisition in 2019
Japonesque LLC is a beauty care company based in San Ramon, California, specializing in high-quality cosmetics and professional beauty tools. Founded in 1984, Japonesque draws inspiration from the traditional makeup techniques of Kabuki theater in Japan, offering a product range that includes makeup brushes, eyelash curlers, nail care tools, and cosmetics designed for both professionals and beauty enthusiasts. The company’s offerings feature innovative formulations and luxurious packaging, catering to the needs of discerning customers seeking both performance and aesthetic appeal. Japonesque products are available through various retail channels in the United States, as well as beauty supply stores, salons, and spas worldwide, ensuring accessibility for a global clientele.

SetPoint Medical

Venture Round in 2019
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

ORIC Pharmaceuticals

Series D in 2019
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.

Rapt

Series C in 2019
RAPT Therapeutics, Inc., established in 2015 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company specializing in immunology-based therapies. The company focuses on developing oral small molecule treatments for patients with unmet needs in oncology and inflammatory diseases. Its lead drug candidates are FLX475, an oral C-C motif chemokine receptor 4 antagonist in Phase 2 clinical trials for various cancer types, and RPT193, which selectively inhibits type 2 T helper cell migration into inflamed tissues. Additionally, RAPT is exploring other targets like general control nonderepressible 2 and hematopoietic progenitor kinase 1 in the discovery phase.

Celmatix

Venture Round in 2019
Celmatix Inc. is a personalized medicine company focused on women's health, particularly in reproductive health and fertility. The company offers POLARIS, a web-based analytics platform designed to optimize a woman's fertility by assessing her likelihood of success with various treatment options based on individual clinical metrics. Additionally, Celmatix provides NOVA, a patient portal that enhances the clinic experience for patients. By leveraging predictive analytics and genomics, the company develops products that empower women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has established a strategic alliance with Evotec and is recognized for possessing the largest structured dataset on ovarian health and outcomes globally. Founded in 2009 and headquartered in New York, Celmatix is also involved in innovative research areas such as ovarian senescence and non-hormonal contraceptives.

Peloton Therapeutics

Series E in 2019
Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for cancer and other serious conditions. Its lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, PT2977 is being tested in various combinations and settings, including von Hippel-Lindau disease associated renal cell carcinoma and glioblastoma multiforme. The company is also working on PT2567, another HIF-2a inhibitor in preclinical development targeting non-oncology conditions such as pulmonary arterial hypertension. Founded in 2010 by Steven L. McKnight and supported by the Cancer Prevention Research Institute of Texas and experienced investors, Peloton aims to leverage its scientific collaborations and robust pipeline to establish itself as a leading biotech firm in cancer drug discovery and development.

Constellation Pharmaceuticals

Series F in 2018
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Rapt

Series C in 2017
RAPT Therapeutics, Inc., established in 2015 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company specializing in immunology-based therapies. The company focuses on developing oral small molecule treatments for patients with unmet needs in oncology and inflammatory diseases. Its lead drug candidates are FLX475, an oral C-C motif chemokine receptor 4 antagonist in Phase 2 clinical trials for various cancer types, and RPT193, which selectively inhibits type 2 T helper cell migration into inflamed tissues. Additionally, RAPT is exploring other targets like general control nonderepressible 2 and hematopoietic progenitor kinase 1 in the discovery phase.

Remedy Health Media

Acquisition in 2017
Remedy Health Media is a digital health platform that provides health-related information to consumers and caregivers in the United States. Established in 1994 and headquartered in New York, the company publishes various health magazines, including Diabetes Focus and MediZine's Healthy Living, as well as digital resources like Healthcommunities.com, which features a symptom checker and expert Q&A. Remedy Health Media aims to empower patients and caregivers by offering accessible content, tools, and authentic community interactions with health professionals. Additionally, it publishes Remedy, which shares insights from health experts, and RemedyKids, focused on children's health information. The company's products and services are designed to help individuals navigate the healthcare landscape more effectively, ultimately contributing to improved health outcomes. Publications are distributed through retail partners, pharmacy counters, and doctors' offices.

Bear Down Brands

Venture Round in 2017
Bear Down Brands is a network of consumer brands that each focus on premium home, health, and personal care products.Bear Down Brands mission is to create elegant, practical, and innovative products that enhance the way you care for yourself and the world around you.Bear Down's focus has been on developing a well-rounded product portfolio while providing advanced product technologies, award-winning customer support, and strong brand relationships with our consumers.

Codagenix

Venture Round in 2017
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.

SetPoint Medical

Series D in 2017
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Hubble

Pre Seed Round in 2017
Hubble is a mobile application designed to facilitate connections among local individuals with shared interests. By leveraging a location-based questions and answers format, the app allows users to pose inquiries to nearby individuals, fostering community engagement and enabling meaningful conversations beyond typical meetups. This innovative platform helps users access hyperlocal information efficiently, eliminating the need to sift through various reviews and websites, thus saving time and enhancing the discovery of local insights.

Constellation Pharmaceuticals

Series E in 2017
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

PMV Pharmaceuticals

Series B in 2017
PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

Palmetto Moon

Acquisition in 2016
Palmetto Moon, LLC is a retail company based in Charleston, South Carolina, specializing in apparel, footwear, and gifts for men, women, and children. Founded in 2002, it offers a wide range of products, including T-shirts, jackets, dresses, accessories, and footwear such as sandals and boots. The company emphasizes collegiate, coastal, and southern living in its product offerings, which also include home goods like blankets, décor, and outdoor gear. Palmetto Moon operates multiple store locations throughout the southeastern United States, including cities in North Carolina and South Carolina, and provides an online shopping platform to reach a broader customer base.

Texas Family Fitness

Acquisition in 2016
Texas Family Fitness, LLC operates a network of health and fitness clubs across Texas, with locations in Coppell, The Colony, Frisco, Plano, and Allen. The company provides a family-friendly environment featuring state-of-the-art equipment and a variety of fitness options, including cardio, dance, yoga, and strength training classes. Personal training services are also available at an affordable monthly rate. By focusing on a family-oriented approach, Texas Family Fitness aims to create a healthy atmosphere for all members while maintaining competitive pricing that offers better value than local competitors.

Rapt

Series B in 2016
RAPT Therapeutics, Inc., established in 2015 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company specializing in immunology-based therapies. The company focuses on developing oral small molecule treatments for patients with unmet needs in oncology and inflammatory diseases. Its lead drug candidates are FLX475, an oral C-C motif chemokine receptor 4 antagonist in Phase 2 clinical trials for various cancer types, and RPT193, which selectively inhibits type 2 T helper cell migration into inflamed tissues. Additionally, RAPT is exploring other targets like general control nonderepressible 2 and hematopoietic progenitor kinase 1 in the discovery phase.

Polder Housewares

Acquisition in 2016
Polder is a manufacturer of housewares products. They offer products that include kitchen, bathroom, laundry, cooking, baking, grilling, sinkware, and storage.

Alector

Series D in 2016
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Constellation Pharmaceuticals

Series E in 2015
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

ORIC Pharmaceuticals

Series B in 2015
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.

JD Beauty

Acquisition in 2015
JD Beauty Group is the perfect company to ensure that you are on the top of your beauty products game. Their product quality, selection, diversity, and prices are the best in the industry. They are commited to using only the best materials in concert with the finest craftsmanship.

Alector

Series C in 2015
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

ThermoLift

Venture Round in 2015
ThermoLift, Inc. specializes in the development and manufacturing of innovative air conditioning and heat pump systems for both heating and cooling, as well as hot water applications. Established in 2012 and located in Stony Brook, New York, the company targets both residential and commercial markets. ThermoLift is focused on creating a transformative thermally driven heat pump that integrates heating, cooling, and hot water functions into a single device. This technology aims to significantly reduce energy consumption for space conditioning by up to 50%, reflecting the company's commitment to energy efficiency and sustainability.

SynchroPET

Debt Financing in 2015
SynchroPET Inc., founded in 2013 and based in Stony Brook, New York, specializes in developing innovative Positron Emission Tomography (PET) imaging systems tailored for both research and clinical applications. The company's product lineup includes PET/MRI systems designed for comprehensive preclinical research, Mini-PET, a portable imaging device for laboratory use, RatCAP, a buoyant device that allows for unhindered animal movement during imaging, and the Wrist PET Detector, a non-invasive scanner for clinical use. These advanced devices aim to enhance diagnostic accuracy and treatment potential for diseases such as cancer, Alzheimer's, and Parkinson's, by providing high-resolution imaging and quantitative data that facilitate personalized medical treatments and accelerate research in biomedical fields.

Codagenix

Series A in 2015
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.

NGM Biopharmaceuticals

Series D in 2015
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.

Codagenix

Grant in 2014
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.

PlayMonster

Acquisition in 2014
PlayMonster is a prominent designer, manufacturer, and marketer of games, children's puzzles, preschool toys, and teaching tools. The company emphasizes innovation and the growth of its diverse brands and product categories, catering to children, adults, and families alike. In addition to producing engaging and educational toys, PlayMonster focuses on delivering creative activities that foster development and learning. Through its commitment to quality and creativity, PlayMonster has established itself as a key player in the toy and game industry.

HCOA Fitness

Acquisition in 2014
HCOA Fitness is a prominent fitness center operator in Puerto Rico, managing a total of 18 locations, including both female-only and co-ed gyms. With 14 gyms strategically situated across the island, HCOA Fitness provides a wide range of health and wellness offerings. These include an extensive selection of strength and cardiovascular equipment, as well as a variety of group exercise and cycling classes. Additionally, the company offers personal training services to support customers in achieving their fitness goals and maintaining healthy lifestyles.

Immune Design

Series C in 2013
Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

SetPoint Medical

Series C in 2013
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

NGM Biopharmaceuticals

Series C in 2013
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.

GHS Interactive Security

Acquisition in 2013
Customer safety & satisfaction is their goal, and they are proud to hold an A+ rating by the Better Business Bureau. They value their customers and put their safety at the forefront of everything they do. They do this by not only providing state-of-the-art products & exceptional customer service, but also by maintaining strong relationships with their customers, their families, and their communities. GHS’s valued employees and affiliates operate with a high degree of integrity while working side-by-side with their customers to provide customized integrated solutions to meet their specific home, business, and financial needs.

Brighter Dental Care

Private Equity Round in 2012
Brighter Dental Care is a dental service provider catering to individuals aged six and older. The company offers a comprehensive range of services, including regular checkups, cleanings, x-rays, fillings, sealants, and fluorides. Additionally, Brighter Dental Care provides specialized treatments such as orthodontics, teeth whitening, and dental implants. Their team consists of general dentists and specialists dedicated to managing various aspects of oral health, ensuring that patients receive tailored care for their specific needs.

Aragon Pharmaceuticals

Series C in 2012
Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.

Celmatix

Series A in 2012
Celmatix Inc. is a personalized medicine company focused on women's health, particularly in reproductive health and fertility. The company offers POLARIS, a web-based analytics platform designed to optimize a woman's fertility by assessing her likelihood of success with various treatment options based on individual clinical metrics. Additionally, Celmatix provides NOVA, a patient portal that enhances the clinic experience for patients. By leveraging predictive analytics and genomics, the company develops products that empower women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has established a strategic alliance with Evotec and is recognized for possessing the largest structured dataset on ovarian health and outcomes globally. Founded in 2009 and headquartered in New York, Celmatix is also involved in innovative research areas such as ovarian senescence and non-hormonal contraceptives.

Stagnito Business Information

Acquisition in 2012
Stagnito Business Information is the retail industry’s most complete provider of market intelligence and strategic communication resources.

Celmatix

Series A in 2011
Celmatix Inc. is a personalized medicine company focused on women's health, particularly in reproductive health and fertility. The company offers POLARIS, a web-based analytics platform designed to optimize a woman's fertility by assessing her likelihood of success with various treatment options based on individual clinical metrics. Additionally, Celmatix provides NOVA, a patient portal that enhances the clinic experience for patients. By leveraging predictive analytics and genomics, the company develops products that empower women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has established a strategic alliance with Evotec and is recognized for possessing the largest structured dataset on ovarian health and outcomes globally. Founded in 2009 and headquartered in New York, Celmatix is also involved in innovative research areas such as ovarian senescence and non-hormonal contraceptives.

2-20 Records Management

Acquisition in 2011
2-20 Records Management, LLC is an information management company based in Edison, New Jersey, offering a comprehensive suite of records storage and management services. These services include document storage, secure shredding, document destruction, data protection, vault storage, and imaging solutions. The company caters to a diverse clientele, including accounting and architectural firms, financial services, government and healthcare organizations, law firms, pharmaceutical companies, as well as small, mid-size, and enterprise businesses. With operations in Arizona, Florida, Southern California, New York, and Pennsylvania, 2-20 Records Management emphasizes a national presence backed by experienced local teams, ensuring compliance-driven and secure record management tailored to the needs of its clients.

Pulse Veterinary Technologies

Acquisition in 2009
Pulse Veterinary Technologies, LLC is a company based in Alpharetta, Georgia, that specializes in developing and marketing non-invasive therapeutic products for veterinary medicine. Established in 2009, the company offers devices such as VersaTron and VersaTron 4Paws, which are designed to manage musculoskeletal disorders in horses and dogs, alleviating pain and lameness. Additionally, Pulse Veterinary Technologies provides ProTec PRP injectable systems for regenerative applications in veterinary care. The company is recognized for its commitment to high standards in quality and innovation, making its technology a trusted choice for veterinary professionals worldwide.

Hart Systems

Acquisition in 2009
Hart Systems, LLC specializes in developing cloud-based physical inventory management solutions tailored for the retail industry. The company offers a range of services that include client support, account management, help desk assistance, server and data communications support, and training. This comprehensive approach ensures that inventory and store managers are well-prepared and confident in utilizing the inventory management system, enhancing overall operational efficiency for retail businesses.

New Whey Nutrition

Acquisition in 2008
New Whey Nutrition company's line of business includes the wholesale distribution of prescription drugs, proprietary drugs, and toiletries.e Company sells a portfolio of functional beverages and other nutritional products through Wal-mart, Kroger, Vitamin Shoppe and a variety of other retailers and distributors. The company’s best-selling product is New Whey Liquid Protein, an innovative, concentrated protein beverage containing 42 grams of protein with no sugar or fat in 3.8 ounces.

Passport Systems

Series C in 2007
Passport Systems Inc. specializes in designing and developing advanced inspection and detection systems aimed at addressing security threats, particularly in the wake of the 9/11 attacks. Founded in 2002 and headquartered in Billerica, Massachusetts, the company provides both active and passive solutions for the automatic detection, localization, and identification of concealed threats and contraband. Its product offerings include SmartScan 3D, a fixed cargo scanner that facilitates the automated clearance of non-threat cargo while detecting complex threats, and SmartShield, a networked radiation detection system focused on identifying radiological threats. These systems are utilized at various critical locations, such as airports, seaports, and border crossings, to enhance national and international security, ensure manifest verification, and monitor real-time radiation threats, thereby protecting urban populations and large events.

Utrecht

Acquisition in 2007
Utrecht is a specialty retailer focused on providing a wide range of fine art supplies, including paints, paper, canvas, and brushes. The company operates 38 stores across the United States, strategically located near or within prominent colleges and universities, catering to the needs of students and artists. In addition to its physical retail presence, Utrecht also offers a catalogue and an online store, allowing customers to access their products conveniently. The company is known for selling its own brand of art materials, further establishing its position in the art supply market.

Neopolitan Networks

Series A in 2007
Neopolitan Networks, headquartered in Palo Alto, California, serves a broad clientele of small, medium-sized, and large organizations with scalable, flexible, robust networking solutions. They provide organizations with transport, including end-to-end private network solutions, Internet connectivity and robust points-of-presence in our data centers that capitalize on advances in fiber optic and wireless technologies to increase network performance and coverage.

Pionetics

Series C in 2007
Pionetics Corporation specializes in manufacturing innovative water treatment products designed to produce safe and great-tasting drinking water while minimizing wastewater compared to traditional systems. Founded in 1995 and headquartered in San Carlos, California, the company offers a range of products, including water filters, drinking water systems, and water coolers, which cater to household, commercial, and industrial applications. Pionetics also provides installation services and rental options for its water treatment systems. Its products are distributed through authorized dealers both domestically and internationally. The company operates as a subsidiary of Rayne Corporation and is supported by financial backing from Kline Hawkes & Co, NGEN Partners, and Unilever Technology Ventures Fund.

Passport Systems

Series B in 2006
Passport Systems Inc. specializes in designing and developing advanced inspection and detection systems aimed at addressing security threats, particularly in the wake of the 9/11 attacks. Founded in 2002 and headquartered in Billerica, Massachusetts, the company provides both active and passive solutions for the automatic detection, localization, and identification of concealed threats and contraband. Its product offerings include SmartScan 3D, a fixed cargo scanner that facilitates the automated clearance of non-threat cargo while detecting complex threats, and SmartShield, a networked radiation detection system focused on identifying radiological threats. These systems are utilized at various critical locations, such as airports, seaports, and border crossings, to enhance national and international security, ensure manifest verification, and monitor real-time radiation threats, thereby protecting urban populations and large events.

Moose River Media

Acquisition in 2005
Moose River Media is a publisher specializing in print and digital magazines, focusing on high-traffic electronic media, custom communications, and proprietary research. The company produces a range of publications that serve the professional lawn and landscape, tree care, light construction, forestry, and agricultural industries throughout the United States. Its notable titles include magazines and journals such as Farming, Turf, Forest Products Equipment, Superintendent, and Buyer's Guide, making it a key player in delivering industry-specific content and insights to its audience.

Game Trust

Series B in 2005
Game Trust, Inc. is a company focused on providing infrastructure for community and commerce applications within the online gaming and entertainment sectors. Founded in 2002 and headquartered in New York, it develops the Game Frame platform, which is tailored for online casual games. This platform allows website operators and game developers to enhance user experiences by integrating community features and commerce capabilities into both new and existing games. Game Trust serves a diverse clientele of game distributors and developers across the United States and Europe, facilitating a more engaging online entertainment environment. As of 2007, Game Trust operates as a subsidiary of RealNetworks, Inc.

Sensicore

Series C in 2005
Sensicore, Inc., based in Ann Arbor, Michigan, specializes in developing smart sensor systems and sensor networks for automated water testing, data collection, and analysis in both drinking and industrial applications. The company provides a range of products including WaterPOINT, a handheld device that offers various chemistry measurements for on-site testing, and WaterNOW, a web-based platform for data visualization and management. Additionally, Sensicore offers sensor kits and bundles for disinfection and basic water testing, as well as colorimetric test kits for a variety of water quality parameters. Their offerings are designed to support municipalities and industries in monitoring and managing water quality effectively. Founded in 2000, Sensicore operates as a subsidiary of GE Analytical Instruments, Inc.

ArgiNOx Phamaceuticals

Series C in 2005
Arginox Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies. It offers Tilarginine Acetate Injection that inhibits the production of nitric oxide, which is used for the treatment of cardiogenic shocks. Arginox Pharmaceuticals is based in Redwood City, California.

Roche NimbleGen

Series F in 2004
Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

ArgiNOx Phamaceuticals

Series B in 2004
Arginox Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies. It offers Tilarginine Acetate Injection that inhibits the production of nitric oxide, which is used for the treatment of cardiogenic shocks. Arginox Pharmaceuticals is based in Redwood City, California.

Game Trust

Series A in 2003
Game Trust, Inc. is a company focused on providing infrastructure for community and commerce applications within the online gaming and entertainment sectors. Founded in 2002 and headquartered in New York, it develops the Game Frame platform, which is tailored for online casual games. This platform allows website operators and game developers to enhance user experiences by integrating community features and commerce capabilities into both new and existing games. Game Trust serves a diverse clientele of game distributors and developers across the United States and Europe, facilitating a more engaging online entertainment environment. As of 2007, Game Trust operates as a subsidiary of RealNetworks, Inc.

netomat

Series B in 2003
netomat, Inc. specializes in developing websites, applications, and social media services that function seamlessly across various devices, including desktops, tablets, and smartphones. The company offers a range of mobile solutions, such as responsive website design, mobile applications, and location-based services. It also provides web solutions, including websites, microsites, and web applications, alongside social media solutions that facilitate integration with social platforms and offer analytics, contests, and engagement tools. Additionally, netomat delivers creative services focused on user interface and experience design, as well as managed services encompassing cloud hosting, search engine optimization, and e-commerce integration. Its flagship Mobility Server enables organizations to publish web content across numerous mobile devices, while the MediaHub service allows for the management and streaming of video content. Catering to clients in diverse sectors, such as tourism, sports, and entertainment, netomat has established itself as a comprehensive provider of mobile web experience and content management solutions since its founding in 2001. The company is headquartered in New York, New York.

The Tiffen Company

Acquisition in 2003
The Tiffen Company is a manufacturer of imaging accessories catering to both consumer and professional markets in the imaging, motion picture, and broadcast television industries. Founded in 1938 by Steve Tiffen and based in Hauppauge, New York, the company offers a diverse range of products, including optical photographic filters, lens accessories, Steadicam camera stabilizing systems, and Lowel location lighting equipment. Additionally, its product lineup features Domke camera bags, Dfx digital effects software, Listec teleprompters, and Davis & Sanford tripods, among other accessories. Tiffen's extensive offerings support various facets of imaging and videography, emphasizing quality and innovation in the industry.

comScore

Series E in 2003
comScore, Inc. is an information and analytics company that specializes in measuring audiences, consumer behavior, and advertising across various media platforms worldwide. The company provides a comprehensive suite of products and services, such as Media Metrix and Mobile Metrix for measuring web and app performance, Video Metrix for tracking digital video consumption alongside TV metrics, and Plan Metrix for consumer lifestyle insights. Additionally, comScore offers validated Campaign Essentials, which ensures the visibility and safety of digital ad impressions, and Campaign Ratings for evaluating cross-platform campaigns. Its offerings also include TV Essentials, StationView Essentials, and OnDemand Essentials for understanding viewing patterns and transactional tracking. Furthermore, the company provides analytics and optimization tools for advertising campaigns and brand protection. comScore's capabilities extend to movie reporting and analytics, delivering insights into box office performance and audience trends. Founded in 1999 and headquartered in Reston, Virginia, comScore serves over 3,200 clients across more than 75 countries, positioning itself as a leader in audience measurement and analytics.

Sensicore

Series B in 2003
Sensicore, Inc., based in Ann Arbor, Michigan, specializes in developing smart sensor systems and sensor networks for automated water testing, data collection, and analysis in both drinking and industrial applications. The company provides a range of products including WaterPOINT, a handheld device that offers various chemistry measurements for on-site testing, and WaterNOW, a web-based platform for data visualization and management. Additionally, Sensicore offers sensor kits and bundles for disinfection and basic water testing, as well as colorimetric test kits for a variety of water quality parameters. Their offerings are designed to support municipalities and industries in monitoring and managing water quality effectively. Founded in 2000, Sensicore operates as a subsidiary of GE Analytical Instruments, Inc.

Pionetics

Series B in 2003
Pionetics Corporation specializes in manufacturing innovative water treatment products designed to produce safe and great-tasting drinking water while minimizing wastewater compared to traditional systems. Founded in 1995 and headquartered in San Carlos, California, the company offers a range of products, including water filters, drinking water systems, and water coolers, which cater to household, commercial, and industrial applications. Pionetics also provides installation services and rental options for its water treatment systems. Its products are distributed through authorized dealers both domestically and internationally. The company operates as a subsidiary of Rayne Corporation and is supported by financial backing from Kline Hawkes & Co, NGEN Partners, and Unilever Technology Ventures Fund.

Coastal Security Company

Acquisition in 2002
Coastal was a retail and wholesale security alarm monitoring company. Coastal had a history of consistent growth and low customer attrition and we expected a continuation of its growth profile given its industry and geography.

comScore

Series D in 2002
comScore, Inc. is an information and analytics company that specializes in measuring audiences, consumer behavior, and advertising across various media platforms worldwide. The company provides a comprehensive suite of products and services, such as Media Metrix and Mobile Metrix for measuring web and app performance, Video Metrix for tracking digital video consumption alongside TV metrics, and Plan Metrix for consumer lifestyle insights. Additionally, comScore offers validated Campaign Essentials, which ensures the visibility and safety of digital ad impressions, and Campaign Ratings for evaluating cross-platform campaigns. Its offerings also include TV Essentials, StationView Essentials, and OnDemand Essentials for understanding viewing patterns and transactional tracking. Furthermore, the company provides analytics and optimization tools for advertising campaigns and brand protection. comScore's capabilities extend to movie reporting and analytics, delivering insights into box office performance and audience trends. Founded in 1999 and headquartered in Reston, Virginia, comScore serves over 3,200 clients across more than 75 countries, positioning itself as a leader in audience measurement and analytics.

TeraLogic

Venture Round in 2001
TeraLogic designs integrated circuits, software and platforms for digital TV.

Terk Antennas

Acquisition in 2001
Terk Antennas is a manufacturer and distributor specializing in branded radio and television antennas, along with select components for sound and stereo systems. The company operates as a subsidiary of Audiovox, focusing on delivering high-quality products that enhance audio and visual experiences for consumers. With a commitment to innovation and design, Terk Antennas aims to meet the needs of customers seeking reliable reception solutions for their entertainment systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.